TSA increases the sensitivity of human ovarian cancer cell line C13 * to cisplatin in vitro

Objective:To investigate the synergistic effects of a histone deacetylase inhibitor, trichostatin A (TSA), combined with cisplatin (DDP) on cisplatin-resistant ovarian epithelial cancer cell line C13 * . Methods: The effects of TSA and/or DDP on the proliferation of C13 * cells were detected by MTT assay. The clonogenic rate of C13 * cells after DDP or TSA + DDP treatment was determined by clonogenic test. Flow cytometry analysis was used to detect cell apoptosis and analyze cell cycle. The morphology of apoptotic cells was observed by Hochest 33258 staining. ResuIts:The apoptotic rate of C13 * cells was 2. 99% after treatment with TSA 40 nmol/L for 12 h. MTT assay showed that TSA treatment had no significant influence on cell proliferation. Preincubation with a subtoxic concentration of TSA markedly sensitized C13 * cells to DDP treatment compared with those treated with DDP only. The difference was significant when DDP was in the range of 20-30 mmol/L (P 0. 05). Conclusion:Combined treatment with subtoxic concentration of TSA and DDP can increase the sensitivity of DDP-resist-ant human ovarian cancer cell line C13 * in vitro.